NIPPON KAYAKU CO.,LTD. (4272.T)
837JPY
30 Dec 2009
¥-12 (-1.41%)
¥837
--
¥858
¥836
487,000
805,500
¥882
¥396
4272.T
About
Overall
| Beta: | 1.22 |
| Market Cap (Mil.): | ¥151,906.91 |
| Shares Outstanding (Mil.): | 181.49 |
| Annual Dividend: | -- |
| Yield (%): | -- |
Financials
| 4272.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 3.43 | 8.35 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 0.04 | 0.02 |
| ROE: | -- | 0.08 | -0.00 |
UPDATE 1-Spectrum inks deal with Korea's Handok for cancer drug
Nov 23 (Reuters) - Spectrum Pharmaceuticals Inc said Handok Pharmaceuticals Co Ltd will develop and commercialize Spectrum's experimental cancer drug in South Korea as part of a deal valued at more than $19 million.
Nikkei set to move narrowly, eyes on yen and data
TOKYO, Nov 11 (Reuters) - Japan's Nikkei average is expected to edge up on Wednesday after the Dow eked out a new 13-month high, but exporters and tech shares are likely to be weaker due to the yen's continued strength, limiting gains.
UPDATE 1-Spectrum, Nippon Kayaku sign cancer drug deal in Asia
Nov 10 (Reuters) - Spectrum Pharmaceuticals Inc signed an agreement with Japan's Nippon Kayaku Co Ltd to develop and market Spectrum's experimental bladder cancer drug apaziquone in Asia.
Nippon Kayaku <4272.T>-6-month group forecast
CONSOLIDATED EARNINGS ESTIMATES (in billions of yen unless specified)
Nippon Kayaku <4272.T>-2009/10 group forecast
CONSOLIDATED EARNINGS ESTIMATES (in billions of yen unless specified)
Nippon Kayaku <4272.T>-6-month parent forecast
PARENT-ONLY EARNINGS ESTIMATES (in billions of yen unless specified)
Nippon Kayaku <4272.T>-2009/10 parent forecast
PARENT-ONLY EARNINGS ESTIMATES (in billions of yen unless specified)
TABLE-Nippon Kayaku <4272.T>-1qtr group results
3 months ended 3 months ended 6 months to Year to
UPDATE 2-Celgene cancer drug may be less harmful to heart
BOSTON, Aug 5 (Reuters) - Celgene Corp said on Wednesday that pooled results from company-sponsored studies of its Amrubicin drug in relapsed small cell lung cancer showed it might be less toxic to the heart than traditional drugs in the same class.
Nippon Kayaku <4272.T>-2008/09 parent results
Year ended Year ended Year to Six months to
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
